Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix

Journal of Controlled Release

Volumn 69, Issue 1, 2000, Pages 149-158

  Sakiyama Elbert, Shelly E ^a,b   Hubbell, Jeffrey A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b California Institute of Technology   (United States)

Author keywords

Factor XIIIa; Fibrin; Heparin; Nerve growth factor; Nerve regeneration

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FIBRIN; HEPARIN; HEPARIN BINDING PROTEIN; NERVE GROWTH FACTOR; NEUROTROPHIN 3;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; NERVE REGENERATION; POLYMERIZATION; PRIORITY JOURNAL; TISSUE REPAIR;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CHROMATOGRAPHY, AFFINITY; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; FIBRIN; GANGLIA, SPINAL; HEPARIN; MODELS, MOLECULAR; NERVE GROWTH FACTORS; NEUROTROPHIN 3;

EID: 0034601868     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00296-0     Document Type: Article

References (28)

1. Otto D., Unsicker K., Grothe C. Pharmacological effects of nerve growth factor and fibroblast growth factor applied to the transectioned sciatic nerve on neuron death in adult rat dorsal root ganglia. Neurosci. Lett. 83:(1/2):1987;156-160.
2. Rich R., Alexander T., Pryor J., Hollowell J. Nerve growth factor enhances regeneration through silicone chambers. Exp. Neurol. 105:1989;162-170.
3. Varon S., Conner J.M. Nerve growth factor in CNS repair. J. Neurotrauma. 11:(5):1994;473-486.
4. Sakiyama-Elbert S., Hubbell J. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release. 65:(3):2000;389-402.
5. Edelman E., Nugent M., Smith L., Karnovsky M. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J. Clin. Invest. 89:(2):1992;465-473.
6. Lee M., Lander A. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc. Natl. Acad. Sci. USA. 88:1991;2768-2772.
7. Cardin A., Weintraub H. Molecular modeling of protein-glycosaminoglycan interactions. Atherosclerosis. 9:(1):1989;21-32.
8. Schense J., Hubbell J. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem. 10:(1):1999;75-81.
9. Sakiyama S.E., Schense J.C., Hubbell J.A. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering. FASEB J. 13:(15):1999;2214-2224.
10. Presta M., Maier J., Rusnati M., Ragniotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J. Cell. Physiol. 140:(1):1989;68-74.
11. Vlodavsky I., Fuks Z., Ishai-Nichaeli R., Bashkin P., Levi E., Korner G.B.-S., Klagsbrun R.M. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J. Cell. Biochem. 45:(2):1991;167-176.
12. Herbert C., Bittner G., Hubbell J. Effect of fibrinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels. J. Comp. Neurol. 365:(3):1996;380-391.
13. Ichinose A., Tamaki T., Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of α2-plasmin inhibitor to fibrin. FEBS Lett. 152:(2):1983;369-371.
14. Tyler-Cross R., Sobel M., Marques D., Harris R. Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy. Protein Sci. 3:(4):1994;620-627.
15. Fields G., Noble R. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35:(3):1990;161-214.
16. Schense J., Bloch J., Aebischer P., Hubbell J. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat. Biotechnol. 18:(4):2000;415-419.
17. Varon S. The isolation and assay of the NGF proteins. Freid R. Methods in Neurochemistry. 1972;203-209 Marcel Dekker, New York.
18. Forander P., Bjorklund L., Stromberg I. Dose-dependent effects of recombinant human NGF on grafted adult adrenal medullary tissue. Exp. Neurol. 126:(2):1994;168-177.
19. Gazzano-Santoro H., Chen A., Casto B., Chu H., Gilkerson E., Mukku V., Canova-Davis E., Kotts C. Validation of a rat pheochromocytoma (PC12)-based cell survival assay for determining biological potency of recombinant human nerve growth factor. J. Pharm. Biomed. Anal. 21:(5):1999;945-959.
20. Ng N.F., Shooter E.M. Activation of p21ras by nerve growth factor in embryonic sensory neurons and PC12 cells. J. Biol. Chem. 268:(34):1993;25329-25333.
21. Riopelle R.J., Verge V.M., Richardson P.M. Properties of receptors for nerve growth factor in the mature rat nervous system. Brain Res. 427:(1):1987;45-53.
22. Lyon M., Rushton G., Gallagher J. The interaction of the transforming growth factor-βs with heparin/heparan sulfate is isoform-specific. J. Biol. Chem. 272:(29):1997;18000-18006.
23. Prigent S., Lemoine N. The Type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4:1992;1-24.
24. Grande J. Role of transforming growth factor-β in tissue injury and repair. Proc. Soc. Exp. Biol. Med. 214:1997;27-40.
25. Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature. 401:(6749):1999;184-188.
26. Drinkwater C.C., Barker P.A., Suter U., Shooter E.M. The carboxyl terminus of nerve growth factor is required for biological activity. J. Biol. Chem. 268:(31):1993;23202-23207.
27. Bairoch A., Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999. Nucleic Acids Res. 27:1999;49-54.
28. McDonald N.Q., Lapatto R., Murray-Rust J., Gunning J., Wlodawer A., Blundell T.L. New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature. 354:(6352):1991;411-414.